COMP <GO>
SNY vs VRTX // ENTERPRISE SCALE & MARKET CAP
Sanofi ADS (NASDAQ) VS. Vertex Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: SNY 4
— VRTX 8
▲ ENTERPRISE SCALE & MARKET CAP LEADER: VRTX
LAST: $44.34 (+2.81%) • MKT CAP: $105.19B
market-cap
$105.19B
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
market-cap
$136.87B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNY VS. VRTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SNY | VRTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 86.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 20.00% | -10.10 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 29.6x | -8.60 | SNY | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 2.33% | -0.12 | VRTX | /fcf-yield <GO> |
| Operating Margin | 13.90% | 34.80% | -20.90 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 32.90% | -22.00 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | -1.10% | 8.90% | -10.00 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 13.86 | -10.12 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.8 | 57.7 | +1.10 | SNY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.14 | 1.02 | +0.12 | SNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 32.2x | -1.70 | SNY | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $105.19B | $136.87B | -$31.68B | VRTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SNY REV | VRTX REV | SNY GROSS % | VRTX GROSS % | SNY FCF | VRTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $12.00B | — | 86.2% | — | $3.19B |
| FY 2024 | — | $11.02B | — | 86.1% | — | -$790.3M |
| FY 2023 | — | $9.87B | — | — | — | $3.09B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNY // BETA 1.14
VRTX // BETA 1.02